Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

被引：11

作者：

Liu, Ning ^{[1
]}

Yan, Limei ^{[1
]}

Shan, Fengping ^{[2
]}

Wang, Xiaonai ^{[2
]}

Qu, Na ^{[3
]}

Handley, Mike K. ^{[4
]}

Ma, Mingxing ^{[5
]}

机构：

[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China

[2] China Med Univ, Dept Immunol, Coll Basic Med Sci, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China

[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Gynecol, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China

[4] Cytocom Inc, 37 North Orange Ave,Suite 607, Orlando, FL 32801 USA

[5] China Med Univ, Shengjing Hosp, Dept Gen Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China

来源：

TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 04期

关键词：

Low-dose naltrexone; Cervical cancer; Proliferation; Invasion; PI3K; AKT; mTOR; EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS; SNAIL2; LDN;

D O I：

10.1016/j.tranon.2021.101028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer.

引用

页数：8

共 50 条

[31] PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Guerrero-Zotano, Angel
Mayer, Ingrid A.
Arteaga, Carlos L.
CANCER AND METASTASIS REVIEWS, 2016, 35 (04) : 515 - 524
[32] PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression
Fath, Mohsen Karami
Masouleh, Ramtin Akhavan
Afifi, Negin
Loghmani, Shirin
Tamimi, Parham
Fazeli, Alireza
Mousavian, Seyed Ali
Falsafi, Mohammad Mehdi
Barati, Ghasem
PATHOLOGY RESEARCH AND PRACTICE, 2023, 241
[33] LHPP suppresses gastric cancer progression via the PI3K/AKT/mTOR signaling pathway
Wang, Danfang
Li, Jianhui
Li, Wenhan
JOURNAL OF CANCER, 2022, 13 (14): : 3584 - 3592
[34] Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis
McAuliffe, Priscilla F.
Meric-Bernstam, Funda
Mills, Gordon B.
Gonzalez-Angulo, Ana M.
CLINICAL BREAST CANCER, 2010, 10 : S59 - S65
[35] Ilicicolin C suppresses the progression of prostate cancer by inhibiting PI3K/AKT/mTOR pathway
Gan, Xia
Luo, Xiaowei
Chen, Jingqin
Fang, Wenxuan
Nie, Mingyi
Lu, Humu
Liu, Yonghong
Wang, Xueni
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2024, : 1089 - 1104
[36] Rafoxanide promotes apoptosis and autophagy of gastric cancer cells by suppressing PI3K /Akt/mTOR pathway
Liu, Jia-Zhou
Hu, Yi-Lin
Feng, Ying
Guo, Yi-Bing
Li, Yi-Fei
Yang, Jun-Ling
Mao, Qin-Sheng
Xue, Wan-Jiang
EXPERIMENTAL CELL RESEARCH, 2019, 385 (02)
[37] TMAO promotes dementia progression by mediating the PI3K/Akt/ mTOR pathway
Hu, Xiaojuan
Zhang, Yamin
Gu, Cheng
Wu, Ruipeng
Yao, Yuping
Gao, Fulin
Luo, Lulu
Zhang, Yi
TISSUE & CELL, 2023, 81
[38] The Role of the PI3K/AKT/mTOR Signalling Pathway in Male Reproduction
Deng, Chun-Yan
Lv, Mei
Luo, Bin-Han
Zhao, Si-Ze
Mo, Zhong-Cheng
Xie, Yuan-Jie
CURRENT MOLECULAR MEDICINE, 2021, 21 (07) : 539 - 548
[39] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
Li, Huayi
Prever, Lorenzo
Hirsch, Emilio
Gulluni, Federico
CANCERS, 2021, 13 (14)
[40] The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Slomovitz, Brian M.
Coleman, Robert L.
CLINICAL CANCER RESEARCH, 2012, 18 (21) : 5856 - 5864

← 1 2 3 4 5 →